@article{article_610154, title={Experimental Parkinson’s disease models}, journal={Journal of Cellular Neuroscience and Oxidative Stress}, volume={10}, pages={795–795}, year={2018}, DOI={10.37212/jcnos.610154}, author={Ipek, Eda Duygu}, keywords={Experimental Parkinson’s disease,Neurotoxic agents}, abstract={<p style="text-align: justify; "> <span style="font-size: 12px;">Parkinson’s disease (PD) is a neurodegenerative  </span> <span style="font-size: 12px;">disease that develops slowly; however, there is no  </span> <span style="font-size: 12px;">efficient method of early diagnosis, nor is there a cure.  </span> <span style="font-size: 12px;">It is characterized by the relatively selective loss of  </span> <span style="font-size: 12px;">dopaminergic neuronal cells in the substantia nigra pars  </span> <span style="font-size: 12px;">compacta and the presence of alpha-synuclein  </span> <span style="font-size: 12px;">aggregation named as Lewy bodies and Lewy neurites  </span> <span style="font-size: 12px;">in surviving affected neurons. Nigrostriatal  </span> <span style="font-size: 12px;">dopaminergic neurodegeneration is shared with other  </span> <span style="font-size: 12px;">parkinsonian disorders, including some genetic forms of  </span> <span style="font-size: 12px;">parkinsonism, but many of these disorders do not have  </span> <span style="font-size: 12px;">Lewy bodies. An ideal animal model for PD, therefore,  </span> <span style="font-size: 12px;">should exhibit age-dependent and progressive  </span> <span style="font-size: 12px;">dopaminergic neurodegeneration, motor and non-motor  </span> <span style="font-size: 12px;">dysfunction, and abnormal alpha-synuclein pathology.  </span> <span style="font-size: 12px;">A wide range of neurotoxic agents are used to  </span> <span style="font-size: 12px;">induce PD, alterations that are similar with dose  </span> <span style="font-size: 12px;">observed in human PD. These agents are classified  </span> <span style="font-size: 12px;">mainly by administration route and the species involved.  </span> <span style="font-size: 12px;">The toxins that are mainly used in present 6-  </span> <span style="font-size: 12px;">hydroxydopamine, 1-Methyl-4-phenyl-1,2,3,6- </span> <span style="font-size: 12px;">tetrahydropyridine, rotenone, paraquat, reserpine,  </span> <span style="font-size: 12px;">methamphetamine, 3-nitrotyrosine and isoquinoline  </span> <span style="font-size: 12px;">derivatives (Tieu, 2011; McDowell and Chesselet, 2012;  </span> <span style="font-size: 12px;">Bezard et al. 2013). In addition, viral mediated  </span> <span style="font-size: 12px;">expression of human α-synuclein, as well as the  </span> <span style="font-size: 12px;">inoculation of pathogenic α-synuclein species from  </span> <span style="font-size: 12px;">Lewy bodies of PD patients, for accurately modelling  </span> <span style="font-size: 12px;">progressive self-propagating neurodegeneration and  </span> <span style="font-size: 12px;">genetic LRRK2 models (PARK8 gene mutation) has  </span> <span style="font-size: 12px;">been used (Jiang and Dickson, 2018).  </span> <span style="font-size: 12px;">In conclusion, these models are only  </span> <span style="font-size: 12px;">approximations, each possibly holding a certain degree  </span> <span style="font-size: 12px;">of relevance. Thus, researchers should select models  </span> <span style="font-size: 12px;">whose characteristics are most suitable for addressing  </span> <span style="font-size: 12px;">the experimental question. </span> </p>}, number={3}, publisher={Yasemin NAZIROĞLU}